Genital Herpes - Pipeline Insight, 2025
Description
DelveInsight’s, “Genital Herpes - Pipeline Insight, 2025” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Genital Herpes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Genital Herpes: Overview
Herpes genitalis is among the most common sexually transmitted infections. It is caused by the herpes simplex virus type 2 (HSV-2) and also, increasingly, the herpes simplex virus type 1 (HSV-1). Both organisms are enveloped DNA viruses that are sensitive to disinfectants and environmental factors 1. Due to marked genetic homology between HSV-1 and HSV-2 numerous biological similarities and antigenic cross-reactions between the viruses exist. Type-specific epitopes include the viral glycoproteins (g) gG (HSV-1 and HSV-2) and gC (HSV-1). The primary mode of transmission of both HSV-1 and HSV-2 is through direct contact. Initial infection with HSV-1 occurs most often during childhood following the disappearance of maternal antibodies during the first year of life. A visible outbreak consists of single or clustered vesicles on the genitalia, perineum, buttocks, upper thighs, or perianal areas that ulcerate before resolving.
Most women with genital herpes do not know they have it. But, if a person get symptoms with the first outbreak of genital herpes, they can be severe. Genital herpes also can be severe and long-lasting in people whose immune systems do not work properly, such as women with HIV. The first signs of genital herpes usually show up two to 12 days after having sexual contact with someone who has herpes. Symptoms can last from two to four weeks.
Genital herpes is diagnosed through a combination of physical examination and laboratory tests. During the physical examination, a healthcare provider will look for characteristic sores or lesions in the genital area. To confirm the diagnosis, a sample from the sore can be taken and tested using polymerase chain reaction (PCR) or viral culture to detect the presence of herpes simplex virus (HSV). Blood tests may also be conducted to identify antibodies against HSV, which indicate a past or current infection. Early and accurate diagnosis is crucial for managing symptoms and reducing the risk of transmission.
Standard first-line drugs include acyclovir, valacyclovir and famciclovir. The specific antiviral action of these acyclic nucleoside analogues is based on their phosphorylation to monophosphate form by thymidine kinase (TK), the key enzyme of HSV-1 and HSV-2, with subsequent phosphorylation via di- to triphosphate form by cellular enzymes. The triphosphate nucleoside analogues inhibit and fixate the viral DNA polymerase by being incorporated into the growing DNA chain as “false” enzyme substrates. In the case of acyclovir/valacyclovir this leads to chain termination, since hydroxyl groups in the 3′ position, which are essential for further linkage, are missing. Famciclovir may be incorporated into the growing DNA chain.
""Genital Herpes- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Genital Herpes pipeline landscape is provided which includes the disease overview and Genital Herpes treatment guidelines. The assessment part of the report embraces, in depth Genital Herpes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Genital Herpes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Genital Herpes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Genital Herpes Emerging Drugs
Further product details are provided in the report……..
Genital Herpes: Therapeutic Assessment
This segment of the report provides insights about the different Genital Herpes drugs segregated based on following parameters that define the scope of the report, such as:
Genital Herpes: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Genital Herpes therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Genital Herpes drugs.
Genital Herpes Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Genital Herpes: Overview
Herpes genitalis is among the most common sexually transmitted infections. It is caused by the herpes simplex virus type 2 (HSV-2) and also, increasingly, the herpes simplex virus type 1 (HSV-1). Both organisms are enveloped DNA viruses that are sensitive to disinfectants and environmental factors 1. Due to marked genetic homology between HSV-1 and HSV-2 numerous biological similarities and antigenic cross-reactions between the viruses exist. Type-specific epitopes include the viral glycoproteins (g) gG (HSV-1 and HSV-2) and gC (HSV-1). The primary mode of transmission of both HSV-1 and HSV-2 is through direct contact. Initial infection with HSV-1 occurs most often during childhood following the disappearance of maternal antibodies during the first year of life. A visible outbreak consists of single or clustered vesicles on the genitalia, perineum, buttocks, upper thighs, or perianal areas that ulcerate before resolving.
Most women with genital herpes do not know they have it. But, if a person get symptoms with the first outbreak of genital herpes, they can be severe. Genital herpes also can be severe and long-lasting in people whose immune systems do not work properly, such as women with HIV. The first signs of genital herpes usually show up two to 12 days after having sexual contact with someone who has herpes. Symptoms can last from two to four weeks.
Genital herpes is diagnosed through a combination of physical examination and laboratory tests. During the physical examination, a healthcare provider will look for characteristic sores or lesions in the genital area. To confirm the diagnosis, a sample from the sore can be taken and tested using polymerase chain reaction (PCR) or viral culture to detect the presence of herpes simplex virus (HSV). Blood tests may also be conducted to identify antibodies against HSV, which indicate a past or current infection. Early and accurate diagnosis is crucial for managing symptoms and reducing the risk of transmission.
Standard first-line drugs include acyclovir, valacyclovir and famciclovir. The specific antiviral action of these acyclic nucleoside analogues is based on their phosphorylation to monophosphate form by thymidine kinase (TK), the key enzyme of HSV-1 and HSV-2, with subsequent phosphorylation via di- to triphosphate form by cellular enzymes. The triphosphate nucleoside analogues inhibit and fixate the viral DNA polymerase by being incorporated into the growing DNA chain as “false” enzyme substrates. In the case of acyclovir/valacyclovir this leads to chain termination, since hydroxyl groups in the 3′ position, which are essential for further linkage, are missing. Famciclovir may be incorporated into the growing DNA chain.
""Genital Herpes- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Genital Herpes pipeline landscape is provided which includes the disease overview and Genital Herpes treatment guidelines. The assessment part of the report embraces, in depth Genital Herpes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Genital Herpes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Genital Herpes R&D. The therapies under development are focused on novel approaches to treat/improve Genital Herpes.
This segment of the Genital Herpes report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Genital Herpes Emerging Drugs
- Pritelivir: AiCuris
- UB-621: United BioPharma
- GSK 3943104: GlaxoSmithKline
- BNT 163: BioNTech
- ABI-5366: Assembly Biosciences
Further product details are provided in the report……..
Genital Herpes: Therapeutic Assessment
This segment of the report provides insights about the different Genital Herpes drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Genital Herpes
- There are approx. 18+ key companies which are developing the therapies for Genital Herpes. The companies which have their Genital Herpes drug candidates in the most advanced stage, i.e. Phase III include, Pritelivir.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Genital Herpes: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Genital Herpes therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Genital Herpes drugs.
Genital Herpes Report Insights
- Genital Herpes Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Genital Herpes drugs?
- How many Genital Herpes drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Genital Herpes?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Genital Herpes therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Genital Herpes and their status?
- What are the key designations that have been granted to the emerging drugs?
- AiCuris
- United BioPharma
- GlaxoSmithKline
- Assembly Biosciences
- BioNTech
- Innovative Molecules
- Pritelivir
- UB-621
- GSK 3943104
- ABI-5366
- BNT 163
- IM-250
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Genital Herpes: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Genital Herpes– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Pritelivir: AiCuris
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- UB-621: United BioPharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- ABI-5366: Assembly Biosciences
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Genital Herpes Key Companies
- Genital Herpes Key Products
- Genital Herpes- Unmet Needs
- Genital Herpes- Market Drivers and Barriers
- Genital Herpes- Future Perspectives and Conclusion
- Genital Herpes Analyst Views
- Genital Herpes Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
